AVAPRO
Total Payments
$28,632
Transactions
8
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $2,221 | 2 | 2 |
| 2020 | $15.81 | 1 | 1 |
| 2019 | $26,395 | 5 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,966 | 3 | 69.7% |
| Travel and Lodging | $8,637 | 3 | 30.2% |
| Food and Beverage | $28.81 | 2 | 0.1% |
Ad
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $28,616
- E.R. Squibb & Sons, L.L.C. $15.81
Product Information
- Type Drug
- Total Payments $28,632
- Total Doctors 3
- Transactions 8
About AVAPRO
AVAPRO is a drug associated with $28,632 in payments to 3 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2019 to 2021. In 2021, $2,221 was paid across 2 transactions to 2 doctors.
The most common payment nature for AVAPRO is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($19,966, 69.7% of total).